Aisner J, Lee E J
University of Maryland Cancer Center, Baltimore 21201.
Cancer. 1991 Jan 1;67(1 Suppl):215-9. doi: 10.1002/1097-0142(19910101)67:1+<215::aid-cncr2820671302>3.0.co;2-d.
Etoposide (VP-16-213) is an antineoplastic agent with demonstrated efficacy against a broad spectrum of human malignancies, including testicular, germ cell, lung, and other cancers. Etoposide can be synergistic with other agents. As part of combination chemotherapy, etoposide has become a so-called standard in therapies for testicular cancer and small cell lung cancer. Its activity in tumors such as lymphoma and leukemia, as well as solid tumors, identifies etoposide as a highly important chemotherapeutic agent. Cellular and animal models have shown that the cell kill and tumor response depend on both dose and time of exposure. Recent clinical studies again show that dose and schedule of etoposide can have important effects on clinical response to the drug. Further research should now continue: (1) on the use of etoposide as part of initial therapy in several cancers, and (2) in higher doses and prolonged schedules to optimize this agent's potential.
依托泊苷（VP - 16 - 213）是一种抗肿瘤药物，已证明对多种人类恶性肿瘤有效，包括睾丸癌、生殖细胞癌、肺癌和其他癌症。依托泊苷可与其他药物协同作用。作为联合化疗的一部分，依托泊苷已成为睾丸癌和小细胞肺癌治疗中的所谓标准药物。它在淋巴瘤、白血病等肿瘤以及实体瘤中的活性，表明依托泊苷是一种非常重要的化疗药物。细胞和动物模型表明，细胞杀伤和肿瘤反应取决于剂量和暴露时间。最近的临床研究再次表明，依托泊苷的剂量和给药方案对药物的临床反应可能有重要影响。现在应继续进行进一步研究：（1）将依托泊苷用作几种癌症初始治疗的一部分；（2）采用更高剂量和延长给药方案以优化该药物的潜力。
